NeoGenomics, Inc. (NEO)

HEALTH CARE: BIOTECHNOLOGY & LIFE SCIENCES
SIC: SERVICES-TESTING LABORATORIES

12701 COMMONWEALTH DRIVE FORT MYERS, FL 33913

NeoGenomics operates a network of cancer-focused testing laboratories that provides genetic and molecular testing services, including: Cytogenetics testing, which studies normal and abnormal chromosomes and their relationship to disease; Fluorescence In-Situ Hybridization testing, which detects and locates the presence or absence of certain deoxyribonucleic acid (DNA) sequences and genes on chromosomes; flow cytometry testing, which measures the characteristics of cell populations; immunohistochemistry testing, which identifies cell proteins in a tissue section; and molecular testing, which analyzes the DNA and ribonucleic, and the structure and function of genes at a molecular level.

Data as of 2020-08-09
Market Cap4.382 Billion Shares Outstanding110.431 Million Avg 30-day Volume943.141 Thousand
P/E Ratio Dividend Yield EPS-0.05
Price/Sales10.832 Price cash flow ratio253.8 Price free cash flow ratio-78.4
Book Value5.92 Price to Tangible Book13.8 Alpha0.03
Short Interest Ratio % Short Interest to Float R-squared0.086101
BETA0.833014 52-week High/Low41.03 / 18.52 Stddev0.119378
View SEC Filings from NEO instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 9 4 (0.26%)
13F Filers holding this stock: 262 57 (3.73%)
Aggregate 13F shares on 03/31/2020: 92.954 Million 31.726 Million
Aggregate 13F shares on 12/31/2019: 93.437 Million 30.687 Million
Percent change: -0.52% 3.38%
Funds creating new positions: 31 5
Funds Adding to an existing position: 87 16
Funds closing out their position: 18 2
Funds reducing their position: 101 29
Heat Map Ranking for 03/31/2020 480
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding NEO (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding NEO BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

198.9 Thousand total shares from 4 transactions

Exercise Derivative Conversion (M)

228.4 Thousand total shares from 7 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

CARDOZA GEORGE PRESIDENT, PHARMA SERVICES

  • Officer
370,902 2020-08-06 4

HANNAH ALISON L.

  • Director
88,796 2020-08-06 3

BALLIET JENNIFER VP AND CHIEF CULTURE OFFICER

  • Officer
24,980 2020-08-03 3

BONELLO WILLIAM PRESIDENT, INFORMATICS

  • Officer
12,060 2020-08-03 3

VAN OORT DOUGLAS M CHAIRMAN AND CEO

  • Officer
  • Director
2,297,790 2020-08-01 5

SHOVLIN ROBERT J. PRESIDENT, CLINICAL SERVICES

  • Officer
148,270 2020-07-30 5

KELLY MICHAEL AARON

  • Director
1,782 2020-07-30 2

MURPHY KIERAN PIUS SENIOR VICE PRESIDENT

  • Officer
146,586 2020-07-28 0

CROWTHER BRUCE K

  • Director
6,900 2020-07-07 2

DIETER CYNTHIA J CHIEF ACCOUNTING OFFICER

  • Officer
0 2020-06-22 2

HIPP RAYMOND R

  • Director
136,800 2020-05-28 2

JOHNSON KEVIN C

  • Director
55,666 2020-05-28 3

TETRAULT LYNN A.

  • Director
44,351 2020-05-28 1

JONES STEVEN C

  • Director
1,894,165 2020-05-28 9

KANOVSKY STEPHEN M

  • Director
6,117 2020-05-28 1

STAHLER RACHEL A

  • Director
2,698 2020-05-28 2

WEISS LAWRENCE MARTIN CHIEF MEDICAL OFFICER

  • Officer
11,717 2020-03-02 1

PEDULLA DENISE E GENERAL COUNSEL

  • Officer
43,988 2020-03-02 2

MCKENZIE KATHRYN B CHIEF FINANCIAL OFFICER

  • Officer
7,929 2020-03-01 2

DENT MICHAEL T CHIEF EXECUTIVE OFFICER

  • Officer
  • Director
  • 10% Owner
0 2019-12-31 0

GASPARINI ROBERT P

  • Director
1,013,611 2019-04-30 0

VIRAG SHARON CHIEF FINANCIAL OFFICER

  • Officer
10,944 2019-03-01 0

GENERAL ELECTRIC CO

GE MEDICAL SYSTEMS INFORMATION TECHNOLOGIES, INC.

  • FORMER 10% OWNERFORMER 10% OWNER
No longer subject to file 2018-12-14 0

BRODIE STEVEN G. VP - PHARMA OPERATIONS

  • Officer
45,953 2018-10-22 0

ROSS STEVEN A CIO

  • Officer
9,000 2018-05-10 0

BYWATER STEPHANIE K CHIEF COMPLIANCE OFFICER

  • Officer
528 2018-05-01 0

ROBISON WILLIAM J

  • Director
359,474 2017-05-25 0

ALBITAR MAHER CHIEF MEDICAL OFFICER

  • Officer
60,692 2017-04-28 0

MACHULCZ MARK ALAN VICE PRESIDENT OF OPERATIONS

  • Officer
0 2016-01-28 0

HOREL ROBERT H. VICE PRESIDENT GM PATHLOGIC

  • Officer
51,218 2015-12-29 0

JONES STEVEN C EXECUTIVE VP OF FINANCE

ASPEN SELECT HEALTHCARE LP

  • Officer
  • 10% Owner
3,886,629 2015-11-25 0

SMITS MARK W SVP-COMMERCIAL OPERATIONS

  • Officer
9,608 2015-06-01 0

KINDERHOOK, LP

KINDERHOOK GP LLC

KINDERHOOK PARTNERS, LLC

SHAH TUSHAR

CLEARMAN STEPHEN J

  • 10% Owner
5,459,517 2014-01-09 0

DVONCH JEROME J PRINICPAL ACCOUNTING OFFICER

  • Officer
0 2011-05-02 0

MILLER MARYDAWN VICE PRESIDENT OF IT

  • Officer
0 2011-05-02 0

PETERSON PETER M

  • Director
  • 10% Owner
8,191,550 2011-05-02 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

CARDOZA GEORGE - Officer PRESIDENT, PHARMA SERVICES

2020-08-06 M 100,000 $7.15 a 433,402 370,902.00 direct

CARDOZA GEORGE - Officer PRESIDENT, PHARMA SERVICES

2020-08-06 M 100,000 d 0 370,902.00 direct

HANNAH ALISON L. - Director

2020-08-06 M 10,000 d 0 88,796.00 direct

CARDOZA GEORGE - Officer PRESIDENT, PHARMA SERVICES

2020-08-06 S 82,500 $39.35 d 350,902 370,902.00 direct

HANNAH ALISON L. - Director

2020-08-06 M 10,000 $7.27 a 88,796 88,796.00 direct

BONELLO WILLIAM - Officer PRESIDENT, INFORMATICS

2020-08-03 M 1,964 d 78,370 12,060.00 direct

BONELLO WILLIAM - Officer PRESIDENT, INFORMATICS

2020-08-03 M 1,964 $8.03 a 34,060 12,060.00 direct

BALLIET JENNIFER - Officer VP AND CHIEF CULTURE OFFICER

2020-08-03 S 13,000 $39.25 d 24,980 24,980.00 direct

BONELLO WILLIAM - Officer PRESIDENT, INFORMATICS

2020-08-03 M 20,036 d 35,727 12,060.00 direct

BONELLO WILLIAM - Officer PRESIDENT, INFORMATICS

2020-08-03 M 20,036 $7.52 a 32,096 12,060.00 direct

BALLIET JENNIFER - Officer VP AND CHIEF CULTURE OFFICER

2020-08-03 M 13,000 $7.52 a 37,980 24,980.00 direct

BONELLO WILLIAM - Officer PRESIDENT, INFORMATICS

2020-08-03 S 22,000 $38.61 d 12,060 12,060.00 direct

BALLIET JENNIFER - Officer VP AND CHIEF CULTURE OFFICER

2020-08-03 M 13,000 d 7,000 24,980.00 direct

VAN OORT DOUGLAS M - Director - Officer CHAIRMAN AND CEO

2020-08-01 F 5,953 d 2,287,790 2,297,790.00 direct

SHOVLIN ROBERT J. - Officer PRESIDENT, CLINICAL SERVICES

2020-07-30 M 16,724 d 50,173 148,270.00 direct

SHOVLIN ROBERT J. - Officer PRESIDENT, CLINICAL SERVICES

2020-07-30 M 16,724 $19.60 a 229,626 148,270.00 direct

KELLY MICHAEL AARON - Director

2020-07-30 A 1,782 a 1,782 1,782.00 direct

SHOVLIN ROBERT J. - Officer PRESIDENT, CLINICAL SERVICES

2020-07-30 M 66,667 d 0 148,270.00 direct

SHOVLIN ROBERT J. - Officer PRESIDENT, CLINICAL SERVICES

2020-07-30 M 66,667 $7.52 a 212,902 148,270.00 direct

SHOVLIN ROBERT J. - Officer PRESIDENT, CLINICAL SERVICES

2020-07-30 S 81,356 $38.17 d 148,270 148,270.00 direct

KELLY MICHAEL AARON - Director

2020-07-30 A 2,223 a 2,223 1,782.00 direct

DIETER CYNTHIA J - Officer CHIEF ACCOUNTING OFFICER

2020-06-22 A 605 a 605 605.00 direct

DIETER CYNTHIA J - Officer CHIEF ACCOUNTING OFFICER

2020-06-22 A 3,968 a 3,968 605.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments